Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
法米替尼联合卡瑞利珠单抗和白蛋白结合型紫杉醇治疗晚期免疫调节性三阴性乳腺癌 (FUTURE-C-Plus):一项开放标签、单组 II 期试验
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-21-4313
Li Chen #, Yi-Zhou Jiang #, Song-Yang Wu #, Jiong Wu, Gen-Hong Di, Guang-Yu Liu, Ke-Da Yu, Lei Fan, Jun-Jie Li, Yi-Feng Hou, Zhen Hu, Can-Ming Chen, Xiao-Yan Huang, A-Yong Cao, Xin Hu, Shen Zhao, Xiao-Yan Ma, Ying Xu, Xiang-Jie Sun, Wen-Jun Chai, Xiaomao Guo, Xizi Chen, Yanhui Xu, Xiao-Yu Zhu, Jian-